The present invention relates generally to mu3 opiate receptors, cannabinoid receptors, and estrogen surface receptors (ESRs). Specifically, the invention provides methods and materials for identifying mu3 opiate receptor agonists and antagonists, cannabinoid receptor agonists and antagonists, and ESR agonists and antagonists. In addition, the invention provides an isolated nucleic acid molecule that encodes a mu3 opioid receptor, and an isolated mu3 opioid receptor polypeptide. Further, the invention provides methods and materials for treating cancers, inflammatory conditions, sepsis conditions, viral infections, and cardiovascular diseases.

A invenção atual relaciona-se geralmente aos receptors do opiate mu3, aos receptors do cannabinoid, e aos receptors de superfície do estrogen (ESRs). Especificamente, a invenção fornece métodos e materiais identificando os agonists e os antagonistas do receptor do opiate mu3, os agonists e os antagonistas do receptor do cannabinoid, e os agonists e os antagonistas do ESR. Além, a invenção fornece uma molécula isolada do ácido nucleic que codifique um receptor do opioid mu3, e um polypeptide isolado do receptor do opioid mu3. Mais mais, a invenção fornece métodos e materiais tratando cancers, circunstâncias inflammatory, condições do sepsis, infecções viral, e doenças cardiovascular.

 
Web www.patentalert.com

< (none)

< Monocyte locomotion inhibitory factor

> DNA damaging agents in combination with tyrosine kinase inhibitors

> (none)

~ 00062